Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 17Gastrointestinal Stromal Tumors 10Neoplasms 5Neoplasm Metastasis 4Multiple Myeloma 4Kidney Neoplasms 4Urologic Neoplasms 2Thyroid Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Meningioma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Kidney Diseases 2Gastrointestinal Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma 2Adenoma, Islet Cell 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thymoma 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

temsirolimus 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Rare Tumours × Sunitinib × 1 year × Clear all
NCT01396408 2026-03-27

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Canadian Cancer Trials Group

Phase 2 Active not recruiting
137 enrolled

Advanced Rare Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡